Hematology TimesPost-approval trials for accelerated drugs fall shortAugust 16, 2017AnemiaLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaPharmacy
Hematology TimesDrug granted priority review, breakthrough designation for ECDAugust 8, 2017CythemiasPharmacy
Hematology TimesFDA approves drug to treat 2 types of AMLAugust 4, 2017Leukemia, Myelodysplasia, TransplantationPharmacyAML
Hematology TimesFDA grants drug orphan designation for PNHAugust 3, 2017AnemiaThrombosisPharmacyBleeding Disorders
Hematology TimesFDA approves enasidenib to treat relapsed/refractory AMLAugust 2, 2017Leukemia, Myelodysplasia, TransplantationPharmacyAML
Hematology TimesFDA grants acalabrutinib breakthrough designationAugust 2, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesASCO updates guidelines on antiemetic use in cancer patientsAugust 1, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaHematology NursingPediatricsPharmacyRelated Issues
Hematology TimesFDA grants drug breakthrough designation for AMLJuly 30, 2017Leukemia, Myelodysplasia, TransplantationPharmacyAML
Hematology TimesProduct granted fast track designation for aTTPJuly 27, 2017AnemiaThrombosisPharmacyBleeding Disorders
Hematology TimesHealth Canada approves new use for brentuximab vedotinJuly 26, 2017Lymphoma & Plasma Cell DisordersPharmacyHodgkin LymphomaAggressive Lymphomas
Hematology TimesFDA grants orphan designation to gilteritinib in AMLJuly 21, 2017Leukemia, Myelodysplasia, TransplantationPharmacyAML
Hematology TimesBlinatumomab granted full approval to treat rel/ref BCP-ALLJuly 13, 2017Leukemia, Myelodysplasia, TransplantationPharmacyALL
